Venus Remedies Secures Global First Marketing Authorization for Plerixafor in Saudi Arabia

Venus Remedies Secures Global First Marketing Authorization for Plerixafor in Saudi Arabia​

Venus Remedies Limited, a leading fixed-dosage injectable manufacturer, has secured Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This approval marks the first time the company has received a Marketing Authorization for Plerixafor anywhere in the world.

The achievement signals a strategic transition for Venus Remedies, guiding the company toward complex, higher-value specialty injectables within regulated markets.

Plerixafor is a hematopoietic stem cell mobilizer therapy. It is utilized in conjunction with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. The therapy is considered standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, stated, "This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in. The Kingdom has the largest pharmaceutical market in the GCC and one of the fastest-growing oncology and transplant infrastructures in the region. Plerixafor sits squarely in the kind of therapy class we are building our international portfolio around. These are specialty injectables where clinical complexity and regulatory rigor create durable demand."

Chaudhary added that the approval reflects the company’s ongoing shift toward differentiated specialty therapies in regulated markets.

The approval enables Venus Remedies to commercialize Plerixafor 24mg/1.2ml in Saudi Arabia through its existing international business network, with a primary focus on tertiary oncology centers.

Market Context and Growth Trajectory​

The success in Saudi Arabia is set against a backdrop of rapid growth in the regional healthcare sector.

The Saudi Arabian pharmaceutical market is projected to grow significantly, providing a strong commercial foundation for the specialty injectable market.


The GCC stem cell therapy market, meanwhile, was estimated at USD 1.2 billion in 2024, with Saudi Arabia, the UAE, and Qatar serving as the principal markets.

Global Operational Scope​

Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, noted that Saudi Arabia is the most important commercial market in the GCC for specialty oncology. She stated that the approval provides a direct platform for building hospital partnerships and anchoring further specialty launches across the region.

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is recognized among the 10 leading fixed-dosage injectable manufacturers globally. The company maintains a commercial presence in over 90 countries with a portfolio of 75 products spanning Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America, and the Caribbean region. The company operates nine globally benchmarked facilities in Panchkula, Baddi, and Weme (Germany), alongside 11 overseas marketing offices.

VENUSREM Stock Price Movement​

Shares of Venus Remedies Limited are edging higher to ₹1069.5 as of 1:05 PM, rallying 3.78% in the live market. Trading activity remains robust, with 37,985 shares transacted in the session.